Aurenar closes $5.7M seed round for non-invasive stroke neuromodulation device. Part of a broader capital flow into neurotech — see our deep-dive on neuromodulation trends.
Aurenar, a developer of non-invasive neuromodulation technology for stroke recovery, has closed a $5.7 million seed financing round. The company is working on a device platform that delivers targeted neurostimulation without surgical implantation — positioning it in the fast-growing non-invasive neuromodulation segment.
This is the latest in a series of neurotechnology venture rounds in 2025–2026, signaling sustained investor conviction that stroke care is shifting from a purely pharmaceutical and rehabilitation model toward device-based intervention. Non-invasive approaches — transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), and focused ultrasound — avoid the regulatory and adoption barriers of implantable devices while still offering the potential for targeted neural circuit modulation. Aurenar's specific technology approach has not been publicly detailed, but the funding size and timing place it among a cohort of early-stage companies betting that stroke recovery will be the next large market for non-invasive neurostimulation — following the regulatory and commercial path cleared by depression and OCD indications.
For a deeper look at the clinical evidence and device landscape behind this trend, see our non-invasive neuromodulation technology deep-dive, published July 2026.
Continue reading
AI computational fluid dynamics in medical devices — where it has actually shipped, and what physics-informed models still get wrong.
Learn how to increase medical equipment sales inquiries: optimize your supplier profile, earn the Verified badge, build Repair Reports, and quote well to convert more buyers.
How to verify medical equipment suppliers before paying: certifications, company identity, repair history, and payment protection in one checklist.
